M
Marya Liimatta
Researcher at Pfizer
Publications - 9
Citations - 1252
Marya Liimatta is an academic researcher from Pfizer. The author has contributed to research in topics: Fatty acid amide hydrolase & Anandamide. The author has an hindex of 7, co-authored 7 publications receiving 1159 citations. Previous affiliations of Marya Liimatta include Scripps Research Institute.
Papers
More filters
Journal ArticleDOI
Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain
Kay Ahn,Douglas S. Johnson,Mauro Mileni,David Beidler,Jonathan Z. Long,Michele K. McKinney,Eranthie Weerapana,Nalini Sadagopan,Marya Liimatta,Sarah E. Smith,Lazerwith Scott E,Cory Michael Stiff,Satwik Kamtekar,Keshab Bhattacharya,Yanhua Zhang,Stephen Swaney,Keri Van Becelaere,Raymond C. Stevens,Benjamin F. Cravatt +18 more
TL;DR: Mechanistic and structural studies confirm that PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile, and designate PF- 3845 as a valuable pharmacological tool for in vivo characterization of the endocannabinoid system.
Journal ArticleDOI
Novel Mechanistic Class of Fatty Acid Amide Hydrolase Inhibitors with Remarkable Selectivity
Kyunghye Ahn,Douglas S. Johnson,Laura R Fitzgerald,Marya Liimatta,Andrea Arendse,Tracy Stevenson,Eric T Lund,Richard A. Nugent,Tyzoon K. Nomanbhoy,Jessica P. Alexander,Benjamin F. Cravatt +10 more
TL;DR: The piperidine/piperazine urea may represent a privileged chemical scaffold for the synthesis of FAAH inhibitors that display an unprecedented combination of potency and selectivity for use as potential analgesic and anxiolytic/antidepressant agents.
Journal ArticleDOI
Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain
Kay Ahn,Sarah E. Smith,Marya Liimatta,David Beidler,Nalini Sadagopan,David T. Dudley,Tim Young,Paul Bryan Wren,Yanhua Zhang,Steven Swaney,Keri Van Becelaere,Jacqueline L. Blankman,Daniel K. K. Nomura,Shoba N. Bhattachar,Cory Michael Stiff,Tyzoon K. Nomanbhoy,Eranthie Weerapana,Douglas S. Johnson,Benjamin F. Cravatt +18 more
TL;DR: Based on its exceptional selectivity and in vivo efficacy, combined with long duration of action and optimal pharmacokinetic properties, PF-04457845 is a clinical candidate for the treatment of pain and other nervous system disorders.
Journal ArticleDOI
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor
Douglas S. Johnson,Cory Michael Stiff,Lazerwith Scott E,Suzanne Ross Kesten,Lorraine Kathleen Fay,Mark Morris,David Beidler,Marya Liimatta,Sarah E. Smith,David T. Dudley,Nalini Sadagopan,Shobha N. Bhattachar,Stephen J. Kesten,Tyzoon K. Nomanbhoy,Benjamin F. Cravatt,Kay Ahn +15 more
TL;DR: Compound 23 has exquisite selectivity for FAAH relative to other members of the serine hydrolase superfamily as demonstrated by competitive activity-based protein profiling and is being evaluated in human clinical trials.
Journal ArticleDOI
Structure-guided inhibitor design for human FAAH by interspecies active site conversion
Mauro Mileni,Douglas S. Johnson,Zhigang Wang,Daniel S. Everdeen,Marya Liimatta,Brandon Pabst,Keshab Bhattacharya,Richard A. Nugent,Satwik Kamtekar,Benjamin F. Cravatt,Kay Ahn,Raymond C. Stevens +11 more
TL;DR: A 2.75-Å crystal structure of h/rFAAH complexed with an inhibitor, N-phenyl-4-(quinolin-3-ylmethyl)piperidine-1-carboxamide (PF-750), that shows strong preference for human FAAH is reported, offering compelling insights to explain the species selectivity of FAAH inhibitors, which should guide future drug design programs.